Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report

Eris Tollkuci

Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report

2019

Eris Tollkuci

Midostaurin is the first approved FMS-related tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 mutated acute myeloid leukemia. Midostaurin is a major cytochrome P450 3A4 (CYP3A4) substrate. Co...

Keywords:

Intensive care medicine
Myeloid leukemia
Midostaurin
Medicine
Anesthesia
Leukocytosis
Drug interaction
Cancer research
CYP3A4
Induction chemotherapy
Lung
Acute leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations